The OCEANUS study, a large-scale real-world analysis, has shed light on the optimal integration of radiotherapy and immunotherapy in advanced non-small cell lung cancer (NSCLC). The study, conducted by Han Zhou and colleagues, aimed to address several unanswered questions in this field, such as the timing of radiotherapy and immunotherapy delivery and the role of chemotherapy in combined treatment strategies. The findings offer valuable insights for clinicians treating advanced NSCLC, emphasizing the importance of context-dependent treatment sequencing.
One of the key findings of the OCEANUS study was the apparent advantage of sequential treatment over concurrent administration of radiotherapy and immunotherapy in newly diagnosed advanced NSCLC. This finding is supported by observations from the PACIFIC trial, where patients received durvalumab after completion of chemoradiotherapy. In contrast, several studies evaluating concurrent immunotherapy during radiotherapy have produced less convincing results. The study found that patients treated with sequential immunoradiotherapy experienced significantly longer survival compared with those receiving concurrent treatment, with a median overall survival of 20.3 months versus 16.0 months, respectively.
The survival advantage associated with sequential treatment appeared most pronounced among patients receiving definitive-dose radiotherapy, which is generally used in patients with unresectable locally advanced disease. In this subgroup, sequential treatment was associated with a marked improvement in survival, with a hazard ratio (HR) of 0.49. By contrast, no statistically significant benefit was observed among patients receiving palliative radiotherapy or among those presenting with de novo metastatic disease.
The study also explored the role of immunotherapy maintenance after radiotherapy in refractory disease. Patients who restarted immune checkpoint inhibition following radiotherapy demonstrated numerically longer survival than those who did not receive maintenance immunotherapy, with a median overall survival of 11.2 months versus 6.7 months, respectively. Although these differences did not reach statistical significance, the magnitude of improvement suggests that selected patients may derive benefit from continued immune stimulation after local radiation therapy.
As immunotherapy becomes increasingly dominant in NSCLC management, the value of chemotherapy within combined treatment strategies continues to be debated. The OCEANUS analysis demonstrated that chemotherapy remained associated with improved outcomes in newly diagnosed advanced disease, but its benefit appeared highly dependent on clinical context. Among newly diagnosed patients receiving immunoradiotherapy, chemotherapy was associated with longer survival, particularly in patients treated with concurrent immunoradiotherapy.
However, chemotherapy failed to improve survival in refractory disease, regardless of whether immunotherapy maintenance was administered. These findings suggest that chemotherapy may retain an important role during initial treatment but becomes less valuable once patients develop treatment-resistant disease. The study also emphasized that the optimal integration of radiotherapy and immunotherapy is highly context dependent, with disease stage, treatment intent, radiation dose, prior therapies, and patient fitness all appearing to influence outcomes.
In conclusion, the OCEANUS study provides some of the strongest real-world evidence to date regarding the optimal integration of radiotherapy and immunotherapy in advanced NSCLC. Sequential immunoradiotherapy was associated with superior survival compared with concurrent treatment, particularly among patients receiving definitive radiotherapy. The study offers important practical lessons for clinicians treating advanced NSCLC, emphasizing the importance of context-dependent treatment sequencing and the potential role of immunotherapy maintenance after radiotherapy in refractory disease. As prospective trials continue to investigate immunoradiotherapy combinations, OCEANUS offers valuable insight into how radiotherapy, immunotherapy, and chemotherapy may be most effectively combined to improve outcomes for patients with advanced NSCLC.
